Whole Genome Sequencing of Single-Circulating Tumor Cell Ameliorates Unraveling Breast Cancer Heterogeneity
Yongping Li,Xiaofei Jiang,Ming Zhong,Bo Yu,Hao Yuan
DOI: https://doi.org/10.2147/BCTT.S388653
2022-12-28
Breast Cancer: Targets and Therapy
Abstract:Yongping Li, 1 Xiaofei Jiang, 1 Ming Zhong, 1 Bo Yu, 2 Hao Yuan 1 1 Department of Breast Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, People's Republic of China; 2 Department of Vascular Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, People's Republic of China Correspondence: Hao Yuan, Department of Breast Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Pudong New Area, Shanghai, 201399, People's Republic of China, Tel +86 18918790382, Email Bo Yu, Department of Vascular Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Pudong New Area, Shanghai, 201399, People's Republic of China, Tel +86 18918922698, Email Objective: Because tumor tissues are most frequently heterogeneous and hard to characterize, the resulting therapeutic strategy could be misled. The most active and invasive tumor cells are circulating tumor cells (CTCs). In this study, we investigated the feasibility of individualized treatment of breast cancer patients based on whole genome sequencing (WGS) of single cell CTC. Methods: Twenty-four CTCs were identified in three breast cancer patients. For each patient, one polyploid CTC was captured, and on which the WGS was performed. WGS was considered due to its sequencing robustness compared to conventional sequencing approaches. Based on the histopathological Her-2 status in tumor tissue and the HER2 gene status in WGS results of CTC, we adjusted treatment strategies and monitored disease progression. Results: Patients ID1 and ID2 are found to be Her-2 positive in primary tumors and HER2 gene amplification in the DNA of CTCs. In-patient ID3, histopathological examination of the primary tumor and liver metastases revealed Her-2 negative, but the WGS analysis of CTC showed HER2 gene amplification. After adjusting treatment by adding Her-2 inhibitors according to the results of CTC sequencing, liver metastases and pleural effusion were significantly reduced two months later, CTC number and ctDNA burden were decreased, and 18-months progression-free survival (PFS) was recorded. In addition, some potential therapeutic targets and mutations in drug-resistant genes were detected. Conclusion: The results of CTC sequencing effectively guided the treatment of a patient with HER2 gene amplification in CTC but with Her-2 negative on tumor tissue. Therefore, CTC sequencing could help resolve the heterogeneity of tumors and provide precision medicine for patients. Keywords: single circulating tumor cell, breast cancer, heterogeneity, whole genome sequencing, HER2 gene The incidence of women's breast cancer is expanding quickly and ranks first, and morbidity trends are increasing, according to the most recent data on cancer in China and worldwide. 1–4 The typical survival period after diagnosis of advanced breast cancer is two to three years. Only 5–10% of patients have a five-year survival rate. 5 Various therapies are integrated based on the patient's tumor condition to develop an efficient and comprehensive treatment approach. 6 Targeted therapy is a widely used treatment option for patients who have significant immunohistochemical (3+) or immunofluorescence in situ hybridization (FISH)-confirmed expression of Her-2 (2+) in their tissue samples. Patients with HER2 /Her-2 positive status have significantly improved results, potentially leading to currently available HER2 -targeting medications. 7 When selecting patients for targeted treatment, accurate and precise identification of this characteristic is essential. However, the IHC/FISH approach, primarily used to examine the Her-2 status on tissue, cannot indicate the precise gene status in the patient's tumors since the HER2 gene status between primary and metastatic tumors may vary. Highly active tumor cells called circulating tumor cells (CTCs), a liquid biopsy material, separate from solid tumors and enter the peripheral circulation. It has been reported that CTCs are linked to tumor metastasis and come from highly invasive malignancies. 8 According to early research, CTCs are highly connected with the prognosis and survival of several solid tumors, including metastatic breast cancer, 9 prostate cancer, 10 and colorectal cancer. 11 A recent study also demonstrated the use of CTC as a possible biomarker for patient classification and the selection of targeted therapies. 12 Multiple tumor tissue samples are challenging to collect in advanced and metastasi -Abstract Truncated-